Stefanie C. Nigro, PharmD, BCACP, CDE, BC-ADM

home / authors / stefanie-c-nigro-pharmd-bcacp-cde-bc-adm

Articles

Interactive Case Studies: November 2021

Interactive Case Studies: November 2021

Stefanie C. Nigro, PharmD, BCACP, CDE, BC-ADM
November 22nd 2021

Read More

Interactives: Case Studies (May 2020)

Interactives: Case Studies (May 2020)

Quinn LaCasse, PharmD candidate;Stefanie C. Nigro, PharmD, BCACP, CDE, BC-ADM
May 31st 2020

Two interactive case studies are featured.

Read More

Interactives: Case Studies (April 2020)

Interactives: Case Studies (April 2020)

Stefanie C. Nigro, PharmD, BCACP, CDE, BC-ADM
April 24th 2020

Two retail pharmacy case studies are presented.

Read More

Interactives: Case Studies (March 2020)

Interactives: Case Studies (March 2020)

Stefanie C. Nigro, PharmD, BCACP, CDE, BC-ADM
March 28th 2020

What would you recommend for these patients?

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD